April.2014-March.2015

Announcement of the commencement of T cell receptor _TCR_ analysis business

Announcement of a patent registration

Announcement of the receipt of a milestone payment associated with the commencement of a Phase III clinical trial of the cancer-specific peptide vaccine S-588410

Announcement of an agreement with Shionogi & Co., Ltd. on Phase III clinical trial of the cancer-specific peptide vaccine S-588410

Publication from our collaborator in The University of Chicago

A press release from Kumamoto University regarding a clinical study using three cancer-specific peptide vaccines

Receipt of a grant for translational research using our compound

Publication of a manuscript describing the development of a small molecule compound causing complete regression of tumors in mice model

Announcement of the first-patient enrollment in phase I clinical trial of the out-licensed antibody from the Consolidated Subsidiary of OncoTherapy

Announcement of issuing the Notice of Acceptance for an Australian patent application

Announcement of the Phase I Clinical Trial activation of the out-licensed antibody from the Consolidated Subsidiary of OncoTherapy

Announcement of the number for patents obtained by OncoTherapy in each fiscal year